Amwill Healthcare IPO subscribed 1.68 times on Day 3 so far: Check GMP, price band and other details
Amwill Healthcare’s SME IPO was fully subscribed 1.68 times by the final bidding day. The retail portion saw 2.41x demand, while QIBs subscribed 2.19x. The IPO price band is Rs 105-111, with allotment on February 10 and listing on February 12. The...

The retail portion of Amwill Healthcare's SME IPO was subscribed 2.41 times, while non-institutional investors subscribed to 81% of their allocated quota. Meanwhile, demand from qualified institutional buyers (QIBs) remained steady at 2.19 times.
The IPO includes a fresh equity sale worth Rs 49 crore and an offer for sale (OFS) of approximately Rs 11 crore. Investors can submit their bids until February 7
Price band for Amwill Healthcare IPO
Amwill Healthcare has set its IPO price range between Rs 105 and Rs 111 per share, with a minimum bid lot size of 1,200 shares. The allocation structure reserves 20% for institutional investors, 40% for retail investors, and the remaining 40% for non-institutional investors.
Amwill Healthcare IPO GMP
Amwill Healthcare had a grey market premium (GMP) of approximately Rs 10-11 before the listing, reflecting a 9% premium over the issue price.
Amwill Healthcare IPO details
Amwill is a derma-cosmetic development company, associated with contract manufacturers, distributor and third party product development agencies, which has enabled it in developing capabilities, in manufacturing, packaging and distribution.
India’s $14 billion beauty and personal care industry is on a roll thanks to online sales of beauty products, premiumisation, and an inclination towards organic and ethical brands.
With the presence of online retailers like Nykaa.com and Amazon.com, the beauty and personal care products category crossed $400 million in internet sales up from $100 million in 2014. The cosmetics sector will continue to expand, reflecting the changing market trends.
Allotment and listing date of Amwill Healthcare IPO
Also read: ITC shares drop 2% after Q3 PAT declines 7% YoY. Should you invest?
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Download ET Markets APP